ストックスクリーナーアプリを入手
29.00
0.21%
-0.06
アフターアワーズ：
27.85
-1.15
-3.97%
前日終値:
$29.06
開ける：
$28.66
24時間の取引高:
613.74K
Relative Volume:
1.83
時価総額：
$199.17M
収益：
-
当期純損益:
$-112.46M
株価収益率:
-17.68
EPS:
-1.64
ネットキャッシュフロー:
$-99.89M
1週間 パフォーマンス:
-7.14%
1か月 パフォーマンス:
-4.61%
6か月 パフォーマンス:
+123.08%
1年 パフォーマンス:
+102.26%
1日の値動き範囲:
$28.65
$31.31
1週間の範囲:
$28.65
$33.42
52週間の値動き範囲:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
VOR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
29.00 | 199.17M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-15 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | アップグレード | Stifel | Hold → Buy |
| 2025-06-30 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | 開始されました | Wedbush | Outperform |
| 2022-04-27 | 開始されました | Goldman | Neutral |
| 2021-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2021-12-03 | 開始されました | Robert W. Baird | Outperform |
| 2021-12-02 | 開始されました | Oppenheimer | Outperform |
| 2021-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-03-25 | 開始されました | B. Riley Securities | Buy |
| 2021-03-03 | 開始されました | Barclays | Overweight |
| 2021-03-03 | 開始されました | Evercore ISI | Outperform |
| 2021-03-02 | 開始されました | Goldman | Sell |
| 2021-03-02 | 開始されました | Stifel | Buy |
すべてを表示
Vor Biopharma Inc (VOR) 最新ニュース
Vor Biopharma (VOR) shareholder reprogrammed interchange sells $2.35 million in stock - Investing.com
Vor Biopharma (VOR) shares sold by RA Capital for $13.7 million - Investing.com Australia
Vor Bio Announces Late-Breaking Oral Presentation of China - GlobeNewswire
Can machine learning forecast Vor Biopharma Inc. recoveryWeekly Investment Summary & Community Consensus Stock Picks - newser.com
Can Vor Biopharma Inc. stock maintain operating marginsJuly 2025 Closing Moves & Advanced Swing Trade Entry Alerts - newser.com
Vor Bio (VOR) Shares Positive Phase 3 Study Results for Telitaci - GuruFocus
Can Vor Biopharma Inc. stock resist sector downturnsPortfolio Update Summary & Free Risk Controlled Daily Trade Plans - newser.com
Vor Biopharma (VOR) 10% owners sell shares worth $3 million By Investing.com - Investing.com Nigeria
Vor Biopharma (VOR) 10% owners sell shares worth $3 million - Investing.com India
Reid Hoffman-linked entity reports VOR sales; 1,278,118 shares held - Stock Titan
Baird Upgrades Vor Biopharma (VOR) - Nasdaq
Baird Upgrades Vor Biopharma to Outperform From Neutral, Adjusts Price Target to $64 From $20 - MarketScreener
Vor Biopharma's Telitacicept: A Pipeline In Itself? - RTTNews
VOR Biopharma (VOR) Receives Significant Analyst Upgrade from Ba - GuruFocus
Baird upgrades Vor Biopharma stock rating to Outperform on telitacicept potential - Investing.com
Baird Upgrades Vor Biopharma, Inc. (VOR) to Outperform - StreetInsider
Combining price and volume data for Vor Biopharma Inc.Weekly Investment Summary & AI Optimized Trading Strategy Guides - newser.com
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears - Benzinga
Vor Biopharma stock rises after positive Phase 3 results for Sjögren’s treatment By Investing.com - Investing.com South Africa
Vor Biopharma stock rises after positive Phase 3 results for Sjögren’s treatment - Investing.com Australia
Vor Bio rises after partner RemeGen succeeds in Sjögren’s disease study - Seeking Alpha
Vor Bio (VOR) and RemeGen Report Strong Phase 3 Results for Teli - GuruFocus
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Reprogrammed Interchange Llc Sells 48,884 Shares of Vor Biopharma (NASDAQ:VOR) Stock - MarketBeat
Vor Biopharma (NASDAQ:VOR) Major Shareholder Sells $2,549,123.94 in Stock - MarketBeat
Vor Biopharma Inc.'s (NASDAQ:VOR) Intrinsic Value Is Potentially 55% Above Its Share Price - simplywall.st
Vor Biopharma (VOR) 10% owner sells $4.1 million in stock By Investing.com - Investing.com Australia
Vor Biopharma (VOR) 10% owner sells $4.1 million in stock - Investing.com
Reid Hoffman-linked entity disposes of 124,146 VOR shares at $31.92–$34.34 - Stock Titan
Is Vor Biopharma Inc. stock poised for growth2025 Key Highlights & High Return Stock Watch Alerts - newser.com
Reversal indicators forming on Vor Biopharma Inc. stock2025 Buyback Activity & Verified Short-Term Trading Plans - newser.com
What indicators show strength in Vor Biopharma Inc.Portfolio Performance Summary & Weekly High Potential Stock Alerts - newser.com
What analyst consensus says on Vor Biopharma Inc. stock2025 Retail Activity & Free Daily Entry Point Trade Alerts - newser.com
Is Vor Biopharma Inc. meeting your algorithmic filter criteria2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Vor Biopharma's (VOR) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Vor Biopharma (NASDAQ:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 70,763 Shares - MarketBeat
Vor biopharma $3.5m stock sale by ten percent owner - Investing.com Australia
Vor Biopharma Inc. (VOR) stock price, news, quote and history - Yahoo
Relative strength of Vor Biopharma Inc. in sector analysisJuly 2025 Trade Ideas & Free Technical Confirmation Trade Alerts - newser.com
Published on: 2025-10-09 02:38:01 - newser.com
Vor biopharma $3.5m stock sale by ten percent owner By Investing.com - Investing.com Australia
VOR: Reporting persons disclose open-market sales and 21.9% ownership - Stock Titan
Reid Hoffman/Form 4 reports 98,387 VOR shares sold, 1.50M held - Stock Titan
Can momentum traders help lift Vor Biopharma Inc.Dividend Hike & Low Risk Investment Opportunities - newser.com
Vor Biopharma Inc (VOR) 財務データ
収益
当期純利益
現金流量
EPS
1.84%
0.50%
大文字化:
|
ボリューム (24 時間):